苯他西泮
臨床資料 | |
---|---|
商品名 | Tiadipona (ES) |
AHFS/Drugs.com | 國際藥品名稱 |
給藥途徑 | Oral (tablets) |
ATC碼 | |
法律規範狀態 | |
法律規範 |
|
藥物動力學數據 | |
藥物代謝 | Hepatic |
生物半衰期 | 2–4 hours |
排泄途徑 | Renal |
識別資訊 | |
| |
CAS號 | 29462-18-8 |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.123.659 |
化學資訊 | |
化學式 | C17H16N2OS |
摩爾質量 | 296.39 g·mol−1 |
3D模型(JSmol) | |
| |
|
苯他西泮(英語:Bentazepam[1]),商品名為Thiadipone、Tiadipona,是一種噻吩並二氮䓬,也就是一種苯二氮䓬類似物。[2]
它具有抗焦慮、抗驚厥、鎮靜和骨骼肌鬆弛作用。口服給藥後約2.5小時將達到血漿峰值速率。[3]消除半衰期約為2至4小時。[2][4]苯他西泮是種有效的抗焦慮藥。
嚴重的過量服用苯他西泮可能會導致昏迷和呼吸衰竭。[5] 不良反應包括口乾、嗜睡、乏力、消化不良、便秘、噁心[6]和藥物引起的淋巴細胞性結腸炎與苯他西泮有關。[7][8]嚴重的肝損傷和肝炎也與苯他西泮有關。[9][10][11]雖然苯他西泮引起的肝衰竭被認為是罕見的,但建議對所有服用苯他西泮的患者進行肝功能監測。[12]
參見
參考資料
- ^ DE 2005276
- ^ 2.0 2.1 Gonzalez López F, Mariño EL, Dominguez-Gil A. Pharmacokinetics of tiadipone: a new anxiolytic. International Journal of Clinical Pharmacology, Therapy, and Toxicology. September 1986, 24 (9): 482–4. PMID 2877954.
- ^ Mariño EL, Fernandez Lastra C, Gonzalez Lopez F, Dominguez-Gil A, Garcia Santalla JL, Vorca G, et al. Parametrization by non-linear regression and bayesian estimation of bentazepam in a multiple dosage regimen in humans. International Journal of Clinical Pharmacology, Therapy, and Toxicology. November 1987, 25 (11): 627–32. PMID 3429066.
- ^ Colino CI, Lastra CF, López FG, Ledesma A, Mariño EL. Open-loop feedback control of serum bentazepam concentrations and Bayesian estimation in multiple dosage regimens in patients. International Journal of Clinical Pharmacology, Therapy, and Toxicology. November 1991, 29 (11): 457–62. PMID 1800395.
- ^ Rivas López FA, López Soriano F, Mendoza Cerezo A, Jiménez Ferré J, Azurmendi Rodríguez JI, de la Rubia Nieto MA. [Mixed benzodiazepine poisoning and reversal with flumazenil (Ro 15-1788)]. Revista Espanola de Anestesiologia y Reanimacion. 1989, 36 (1): 48–50. PMID 2565591.
- ^ Honorato J, Rubio A, Tristán C, Otero FJ, Garrido J. [A pharmacovigilance study with bentazepam in a sample of 1046 psychiatric outpatients]. Revista de Medicina de la Universidad de Navarra. 1990, 34 (2): 80–8. PMID 1983365.
- ^ Fernández-Bañares F, Salas A, Esteve M, Espinós J, Forné M, Viver JM. Collagenous and lymphocytic colitis. evaluation of clinical and histological features, response to treatment, and long-term follow-up. The American Journal of Gastroenterology. February 2003, 98 (2): 340–7. PMID 12591052.
- ^ de-la-Serna C, Gil-Grande LA, Sanromán AL, Gonzalez M, Ruiz-del-Arbol L, Garcia Plaza A. Bentazepam-induced hepatic bridging necrosis. Journal of Clinical Gastroenterology. December 1997, 25 (4): 710–1. PMID 9451703. doi:10.1097/00004836-199712000-00042.
- ^ Andrade RJ, Lucena MI, Kaplowitz N, García-Muņoz B, Borraz Y, Pachkoria K, et al. Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. Hepatology. December 2006, 44 (6): 1581–8. PMID 17133470. S2CID 9067701. doi:10.1002/hep.21424 .
- ^ Tuca A. Utilidad clinica del acetato de megestrol para la ganancia de peso en los enfermos con neoplasia y caquexia. Medicina Clinica. 2003, 120 (17): 678 [2023-01-20]. doi:10.1157/13047309. (原始內容存檔於2018-09-16) (西班牙語).
- ^ Andrade RJ, Lucena MI, Alcantara R, Fraile JM. Bentazepam-associated chronic liver disease. Lancet. April 1994, 343 (8901): 860. PMID 7908109. S2CID 33991843. doi:10.1016/S0140-6736(94)92065-6.
- ^ Andrade RJ, Lucena MI, Aguilar J, Lazo MD, Camargo R, Moreno P, et al. Chronic liver injury related to use of bentazepam: an unusual instance of benzodiazepine hepatotoxicity. Digestive Diseases and Sciences. July 2000, 45 (7): 1400–4. PMID 10961721. doi:10.1023/A:1005520523502.